FDA's Drug Review Process and the Package Label: Strategies for Writing Successful FDA Submissions
- ISBN-10
- 0128146486
- ISBN-13
- 9780128146484
- Category
- Business & Economics
- Pages
- 670
- Language
- English
- Published
- 2017-12-13
- Publisher
- Academic Press
- Author
- Tom Brody
Description
FDA's Drug Review Process and the Package Label provides guidance to pharmaceutical companies for writing FDA-submissions, such as the NDA, BLA, Clinical Study Reports, and Investigator's Brochures. The book provides guidance to medical writers for drafting FDA-submissions in a way more likely to persuade FDA reviewers to grant approval of the drug. In detail, the book reproduces data on efficacy and safety from one hundred different FDA-submissions (NDAs, BLAs). The book reproduces comments and complaints from FDA reviewers regarding data that are fragmentary, ambiguous, or that detract from the drug's approvability, and the book reveals how sponsors overcame FDA's concerns and how sponsors succeeded in persuading FDA to grant approval of the drug. The book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely text and data from NDAs and BLAs, as published on FDA's website. The source material for writing this book included about 80,000 pages from FDA's Medical Reviews, FDA's Clinical Pharmacology Reviews, and FDA's Pharmacology Reviews, from one hundred different NDAs or BLAs for one hundred different drugs. Each chapter focuses on a different section of the package label, e.g., the Dosage and Administration section or the Drug Interactions section, and demonstrates how the sponsor's data supported that section of the package label. Reveals strategies for winning FDA approval and for drafting the package label Examples are from one hundred FDA-submissions (NDAs, BLAs) for one hundred different drugs, e.g., for oncology, metabolic diseases, autoimmune diseases, and neurological diseases This book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely, the data from NDAs and BLAs as published on FDA's website at the time FDA grants approval to the drug
Get the book
Similar books
-
FDA's Drug Approval Process: Up to the Challenge? : Hearing of the Committee on Health, Education, Labor, and Pensions, United...
By Education, United States. Congress. Senate. Committee on Health, LaborFDA's Drug Approval Process: Up to the Challenge? : Hearing of the Committee on Health, Education, Labor, and Pensions, United...
-
How FDA Approves Drugs and Regulates Their Safety and Effectiveness
By Susan ThaulFDA uses a few special mechanisms to expedite drug development and the review process when a drug might address an unmet need or a serious disease or condition.
-
How FDA Approves Drugs and Regulates Their Safety and Effectiveness
By Congressional ServiceFDA uses a few special mechanisms to expedite drug development and the review process when a drug might address an unmet need or a serious disease or condition.
-
Revitalizing New Product Development from Clinical Trials Through FDA Review: Hearing of the Committee on Labor and Human Resources, United...
By United States. Congress. Senate. Committee on Labor and Human ResourcesRevitalizing New Product Development from Clinical Trials Through FDA Review: Hearing of the Committee on Labor and Human Resources, United...
-
FDA's Drug and Device Review Process: Hearing Before the Subcommittee on Oversight and Investigations of the Committee on Energy and...
By United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and InvestigationsFDA's Drug and Device Review Process: Hearing Before the Subcommittee on Oversight and Investigations of the Committee on Energy and...
-
Safe and Effective Medicines for Children: Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research...
By Institute of Medicine, Board on Health Sciences Policy, Committee on Pediatric Studies Conducted Under the Best Pharmaceuticals for Children ActAAP also publishes Nelson's Pocket Book ofPediatric Antimicrobial Therapy, which is updated yearly.40 Both of these resources are limited to antimicrobial therapy. Other intermediary resources provide both adult and pediatric dosing.
-
FDA Regulatory Affairs: Third Edition
By Douglas J. Pisano, David MantusThe Third Edition of this highly successful publication: Examines the harmonization of the US Federal Food, Drug, and Cosmetic Act with international regulations on human drug, biologics and device development, research, manufacturing, and ...
-
Prescription Drugs: FDA's Oversight of the Promotion of Drugs for Off-Label Uses
By Marcia CrosseThe FDA regulates the promotion of prescription drugs (PD) to ensure that promotional materials are not false and misleading and that they comply with applicable laws and regulations.
-
From Test Tube to Patient: New Drug Development in the United States
By DIANE Publishing CompanyCovers: laboratory and animal studies, testing in "real people", experimental drugs, watching for problems, myths and facts of generic drugs, and much more. Illustrated.
-
Pill Politics: Drugs and the FDA
By Stephen J. CeccoliAccording to the CSDD , the average FDA review time for approved new chemical entities decreased from 35.6 months in 1984–1986 to 16.8 months in 1996–1998 ( Kaitin and Healy , 2000 ) . Thus , in a little more than a decade , the FDA ...